ArticleEuropean journal of nuclear medicine and molecular imaging2025
Virtual cutaneous area severity index (vCASI): A comprehensive methodology for quantitative skin disease assessment on positron emission tomography images.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeQuantification of skin diseases such as cutaneous lymphoma or psoriasis is important for pretreatment planning and response assessment. Currently, this quantification relies on clinical assessments, which are cumbersome, error-prone, and subject to inter-reader variability. FDG-PET/CT is a widely used molecular imaging technique for non-invasive detection and quantification of metabolically active disorders, providing biomarkers of disease extent, severity, and therapeutic response. However, skin disease quantification from PET/CT images remains challenging, error-prone, and labor-intensive.
methodsWe proposed a novel comprehensive methodology called virtual Cutaneous Area Severity Index (vCASI) to quantitatively assess the extent and severity of metabolically active skin disease from FDG-PET/CT images. Firstly, we used an automated body region localization method, followed by a standardization technique for PET images to reduce interscan measurement variability. Then, we generated skin shell PET images and developed a standardized Maximum Intensity Projection (MIP) rendering technique to enable reproducible 3D visualization of the skin with the disease. Finally, we introduced and validated a new quantitative scoring system (vCASI score) to measure the extent and severity of skin disease via these renderings.
resultsCorrelations between vCASI scores and reference standard ground-truth assessments increased following the standardization of PET images, further improved with the use of adjusted mean of maximum percentile intensity values as the reference point for MIP rendering, and reached as high as 0.605. Additionally, correlations between repeated vCASI score assessments for the torso, thorax, abdomen, and pelvis exceeded 0.85, demonstrating high repeatability.
conclusionsThe vCASI methodology allows for accurate and reproducible quantitative assessment of the extent and severity of metabolically active skin diseases, such as cutaneous lymphoma and psoriasis, from FDG-PET/CT images. It addresses the challenges related to body region localization, non-standardness of PET images, robust visualization, and standardized display of PET images to detect and quantify skin disease. Additionally, it overcomes the lack of a practical and validated scoring system for quantifying skin disease on PET images. We demonstrated that the vCASI scoring system has high repeatability and good accuracy, and is optimized by the proposed methodology.
Indexed as
Identifiers
40545498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.